MedTrace Logo

Phase 1 XG005-03 Topical Study

NCT04283474 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2021-03-25

No results posted yet for this study

Summary

Phase 1, randomized, single-blinded, placebo-control, ascending single and multiple dose of the PK, safety, and tolerability of XG005-03 topical formulation in Healthy Volunteers.

Conditions

Interventions

DRUG

XG005-03

3 different concentrations (1%, 5%, 10%) of XG005-03 topical formulation

DRUG

Placebo

Placebo topical formulation

Sponsors & Collaborators

  • Xgene Pharmaceutical Group

    lead INDUSTRY

Principal Investigators

  • Feng Xu, PHD · Xgene Pharmaceutical Group

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-02-28
Primary Completion
2021-01-28
Completion
2021-01-28

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04283474 on ClinicalTrials.gov